Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
261 stopped studies mapped to Head and Neck Squamous Cell Carcinoma and descendants · 95% state a reason
Over the 261 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and… | Phase 1 | terminated | Jul 31, 2014 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro… | Phase 2 | terminated | Aug 11, 2017 | HiberCell, Inc. | Due to enrollment challenges resulting in changing treatment patterns, the study has been… | Enrollment / accrual |
| NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative… | Phase 1 / Phase 2 | terminated | Nov 26, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Slow accrual and high levels of toxicity lead to early termination. | Safety / toxicity |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus… | Phase 2 | terminated | May 13, 2013 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01164566 | Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer… | N/A | terminated | Jul 16, 2010 | Wake Forest University Health Sciences | Inadequate Recruitment | Enrollment / accrual |
| NCT02552550 | Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx | — | terminated | Sep 17, 2015 | Centre Hospitalier Universitaire de Saint Etienne | rate of inclusion too low | Other (stated, no rule matched) |
| NCT00901537 | Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer | Phase 1 | terminated | May 14, 2009 | Loma Linda University | Sponsor terminated due to no enrollments within last 4 months. | Enrollment / accrual |
| NCT02365662 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced… | Phase 1 | terminated | Feb 19, 2015 | AbbVie | Safety | Safety / toxicity |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | Phase 2 | terminated | Nov 15, 2013 | Nina Bhardwaj | PI discretion, low enrollment | Enrollment / accrual |
| NCT01488318 | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma | Phase 2 | terminated | Dec 8, 2011 | Julie E. Bauman, MD, MPH | PI leaving the institution | Other (stated, no rule matched) |
| NCT02993991 | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous…(PRIMED-001) | Phase 1 | withdrawn | Dec 15, 2016 | University Health Network, Toronto | The study has been terminated due to a change in internal prioritization and not due to any safety… | Safety / toxicity |
| NCT01051791 | Phase II Study of RAD001 Head and Neck Cancer | Phase 2 | terminated | Jan 20, 2010 | Julie E. Bauman, MD, MPH | not stated | Not stated |
| NCT01221753 | Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell… | Phase 2 | terminated | Oct 15, 2010 | Dana-Farber Cancer Institute | Due to slow accrual | Enrollment / accrual |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous… | Phase 1 / Phase 2 | terminated | Dec 11, 2007 | Dana-Farber Cancer Institute | The study did not continue to phase II due to the importance of HPV status as a prognostic factor… | Other (stated, no rule matched) |
| NCT02068157 | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer | Phase 2 | terminated | Feb 21, 2014 | Roswell Park Cancer Institute | Study no longer has an active IDE | Other (stated, no rule matched) |
| NCT02211027 | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | Phase 1 | withdrawn | Aug 7, 2014 | Robert Ferris | not stated | Not stated |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | Phase 1 | terminated | Sep 2, 2015 | Merrimack Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT01303237 | A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus…(PMS LAD SCCHN) | — | terminated | Feb 24, 2011 | Merck KGaA, Darmstadt, Germany | The study was discontinued due to slow recruitment and subjects not completing follow up period. | Enrollment / accrual |
| NCT02593929 | Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and… | Early Phase 1 | withdrawn | Nov 2, 2015 | University of Pittsburgh | not stated | Not stated |
| NCT00895245 | Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing… | Phase 2 | terminated | May 8, 2009 | University of Washington | Study stopped due to lack of efficacy in first 6 patients | Efficacy / futility |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or… | Phase 2 | terminated | Jul 21, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head… | Phase 2 | terminated | Dec 28, 2010 | National Cancer Institute (NCI) | Study treatment did not show clinical activity. | Other (stated, no rule matched) |
| NCT00392665 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | Phase 2 | terminated | Oct 26, 2006 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
| NCT00903461 | Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck… | Phase 1 | terminated | May 18, 2009 | University of Pittsburgh | drug supply issues | Drug supply |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the… | Phase 1 / Phase 2 | terminated | Jan 6, 2015 | Innate Pharma | lack of recruitment | Enrollment / accrual |
| NCT01283178 | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced… | Phase 1 | terminated | Jan 25, 2011 | Virginia Commonwealth University | The study was terminated. The data analysis was futile with only 3 accruals. PI opted to terminate… | Enrollment / accrual |
| NCT02649530 | A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous… | Phase 2 | withdrawn | Jan 7, 2016 | University of Michigan Rogel Cancer Center | funding withdrawn | Funding |
| NCT01975688 | A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis | Phase 1 | terminated | Nov 5, 2013 | GW Pharmaceuticals Ltd | Slow recruitment | Enrollment / accrual |
| NCT01820312 | A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) | Phase 2 | withdrawn | Mar 28, 2013 | University of Arkansas | Due to no enrollment. | Enrollment / accrual |
| NCT01528137 | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer… | Phase 1 | terminated | Feb 7, 2012 | Stanford University | Negative data from another trial led to termination of this trial by sponsor. | Other (stated, no rule matched) |
| NCT02334319 | Ganetespib Window of Opportunity Study in Head and Neck Cancers | Phase 1 | terminated | Jan 8, 2015 | Emory University | Lack of funding | Funding |
| NCT00627835 | Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and… | Phase 1 | withdrawn | Mar 3, 2008 | British Columbia Cancer Agency | Site decided not to open this study | Other (stated, no rule matched) |
| NCT00377247 | Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With… | Phase 1 | terminated | Sep 18, 2006 | University of Pittsburgh | study closed to accrual due to slow accrual | Enrollment / accrual |
| NCT02119728 | Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the… | Phase 2 | withdrawn | Apr 22, 2014 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02143622 | Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell… | Phase 1 / Phase 2 | withdrawn | May 21, 2014 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical…(iNSITE2) | Phase 2 | terminated | Jun 24, 2015 | BIND Therapeutics | not stated | Not stated |
| NCT01285635 | A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head… | Phase 2 | terminated | Jan 28, 2011 | University of Michigan Rogel Cancer Center | drug is no longer manufactured | Drug supply |
| NCT00272181 | Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer | Phase 2 | terminated | Jan 4, 2006 | Sesen Bio, Inc. | Slow accrual in North America | Enrollment / accrual |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | Phase 1 / Phase 2 | withdrawn | Apr 26, 2012 | Dana-Farber Cancer Institute | Local IRB closed the study due to poor accural. | Other (stated, no rule matched) |
| NCT01949740 | Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA… | — | terminated | Sep 24, 2013 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT02156180 | Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma | — | suspended | Jun 5, 2014 | Queensland Centre of Excellence for Head and Neck Cancer | Awaiting funding to facilitate selected-ion flow-tube mass spectrometry (SIFT/MS) | Funding |
| NCT01953952 | Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage… | Phase 2 | withdrawn | Oct 1, 2013 | Radiation Therapy Oncology Group | Slow accrual | Enrollment / accrual |
| NCT01133262 | Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET)… | — | withdrawn | May 28, 2010 | Washington University School of Medicine | Feasibility/pilot study of 5 subjects registration not required | Other (stated, no rule matched) |
| NCT01254734 | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck… | N/A | terminated | Dec 7, 2010 | City of Hope Medical Center | The study will be rewritten as a data registry study | Other (stated, no rule matched) |
| NCT01718223 | Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent… | N/A | withdrawn | Oct 31, 2012 | Roswell Park Cancer Institute | implementation issues | Other (stated, no rule matched) |
| NCT01305772 | Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated…(TOP0901) | Phase 2 | terminated | Mar 1, 2011 | Neal Ready | This study was terminated for low accrual. | Enrollment / accrual |
| NCT01682031 | Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck… | Phase 2 | terminated | Sep 10, 2012 | Roswell Park Cancer Institute | Due to a lack of funding | Funding |
| NCT00911326 | Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma | Phase 3 | terminated | Jun 1, 2009 | Navidea Biopharmaceuticals | The trial was terminated early based on an interim review by the Data and Safety Monitoring… | Safety / toxicity |
| NCT01360827 | EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic… | Phase 1 | terminated | May 26, 2011 | Merck KGaA, Darmstadt, Germany | Study terminated due to potential safety concerns in combination with platinum-based therapies | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 22, 2019source: clinicaltrials